Analyst: The survival of Neurosearch should be secured through capital expansion
Neurosearch is in need of a capital expansion if the company is to raise enough money for its phase III trials of Huntexil, according to an analyst.
It is highly unlikely that the biotech company Neurosearch will succeed in finding a partner for the phase III trials of its Huntington’s drug, Huntexil. That’s the assessment of Peter Aabo, who is an analyst in the independent analysis firm Nordic Bio Investor.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Neurosearch: We are keeping our options open
For abonnenter
Increased FDA demands affect Neurosearch-rights
For abonnenter
.jpg&w=384&q=75)
